Arbor Research Collaborative for Health

More on Arbor Research at American Society of Nephrology (ASN) Kidney Week 2024! Ting Lu, Brian Bieber, Angelo Karaboyas, and Claudio Rigatto at the Arbor Research presentation “Gabapentin Use and Adverse Effects among Hemodialysis Patients Diagnosed with Pruritus or Neuropathic Pain in US Claims Data” yesterday. #ASN2024 #KidneyWeek2024 #Nephrology #Gabapentin #Hemodialysis #CKD #RealWorldEvidence

I'm so glad we got a chance to meet as a team at ASHI. Thanks, Malek, for being the driving force behind the HLA Immunogenetics and Kidney Allograft Outcomes project!

Arbor Research at American Society of Nephrology (ASN) Kidney Week 2024! Angelo Karaboyas, in collaboration with the Arbor Research team, will present the study “Gout Prevalence and Management Strategies among Patients with Moderate to Advanced CKD” on October 25, 2024, from 10:00 AM to 12:00 PM in the Exhibit Hall. This multi-country analysis, part of the CKDopps study, explores the prevalence, patient characteristics, and management of gout in over 3,500 non-dialysis patients with moderate to advanced CKD across the United States and Brazil. With insights into the varied use of treatments like allopurinol and febuxostat, as well as differences in uric acid monitoring practices between the two countries, this study aims to shed light on opportunities for improving patient outcomes. Join us to learn how this research could pave the way for better management of gout in CKD patients globally. Don’t miss out on Angelo's presentation and the valuable findings it brings to the nephrology community. #ASN2024 #KidneyWeek2024 #Nephrology #CKD #Gout #RealWorldEvidence #PatientOutcomes

Arbor Research at American Society of Nephrology (ASN) Kidney Week 2024! Ting Lu of Arbor Research will be presenting the findings of the study “Gabapentin Use and Adverse Effects among Hemodialysis Patients Diagnosed with Pruritus or Neuropathic Pain in US Claims Data” on October 24, 2024, from 10:00 AM to 12:00 PM in the Exhibit Hall. This research explores real-world utilization of gabapentin among over half a million US hemodialysis patients, focusing on its use for managing chronic kidney disease-associated pruritus (CKD-aP) and neuropathic pain (NP). The study reveals important insights into gabapentin dosing patterns, time to discontinuation, and associated risks of adverse events like altered mental status and falls, especially in off-label use for CKD-aP. Don’t miss this chance to gain new perspectives on balancing treatment benefits and risks in managing symptoms for hemodialysis patients. Join us in supporting Ting Lu’s important contribution to the field of nephrology! #ASN2024 #KidneyWeek2024 #Nephrology #Gabapentin #Hemodialysis #CKD #RealWorldEvidence

Arbor Research at American Society of Nephrology (ASN) Kidney Week 2024!  Arbor Research staff will be at Kidney Week 2024. Dr. Roberto Pecoits-Filho, Distinguished Research Scientist with Arbor Research Collaborative for Health, will co-moderate the Oral Abstract Session “Diabetic Kidney Disease - Clinical: Novel Insights into Precision Medicine” on October 24, 2024, at 4:30 PM in Room 33 of the Convention Center, alongside the esteemed Dr. Carol A. Pollock. This session will highlight groundbreaking research that delves into precision medicine approaches for managing diabetic kidney disease (DKD). Attendees will gain insights into new therapeutic strategies, including novel uses of SGLT2 inhibitors, GLP-1 receptor agonists, and endothelin receptor antagonists. The session also explores the role of advanced biomarkers, from urinary proteins and circulating microbial DNA to predictive tools like KidneyIntelX, which promise to revolutionize early diagnosis and treatment of CKD. This is a must-attend event for anyone looking to stay at the forefront of nephrology research and innovation. Join us to learn from leading experts as they present the latest advancements aimed at improving outcomes for patients with diabetic kidney disease. See you at #KidneyWeek2024! #ASN2024 #Nephrology #CKD #PrecisionMedicine #DiabeticKidneyDisease

We're #hiring a new Project Manager II in United States. Apply today or share this post with your network.

Arbor Research to Launch PARADIGM, a European CKD-aP Treatment Registry to Evaluate Real-World Outcomes of Kapruvia® in Hemodialysis Patients Arbor Research Collaborative for Health is excited to announce a partnership with CSL Vifor to launch a multinational registry designed to capture real-world outcomes of difelikefalin (Kapruvia®), a newly-approved treatment for chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis (HD) patients. Known as PARADIGM (PAn european Registry Addressing pruritus in DIalysis with a focus on Goal oriented Medical treatment), the registry will include several hundred initiators of Kapruvia® across five European countries (France, Germany, Italy, Spain, UK), with patient enrollment set to begin in Q1 2025, and follow-up continuing through 2028. Read more here: https://bit.ly/48fKrfk

Arbor Research at the 2024 American Society for Histocompatibility and Immunogenetics Conference Arbor Research is pleased to share that Keith McCullough, Research Scientist, is presenting a poster at the 2024 American Society for Histocompatibility and Immunogenetics conference in Anaheim, CA. The poster, titled “Risk of kidney graft failure (GF) associated with HLA class II amino acid mismatches (AAMM) is highest during the first year after transplant for sensitized patients”, will be shown during the opening reception on October 21 (7-9PM) and during the poster reception on October 22 (6:15-8:15PM). Keith developed this work with Loren Gragert (Tulane University), Nick Brown (University of Pennsylvania), Ryan J. Urbanowicz (Cedars-Sinai Medical Center), Alyssa N. Paynter (Tulane University), and Malek Kamoun (University of Pennsylvania). Stop by and see !

It was powerful to be at the PSC Partners annual conference in Phoenix this past weekend. Throughout the conference, I shared meals and time between sessions with patients living with PSC, a rare liver disease for which there is currently no treatment or cure. Through hours of conversations, I learned about their experiences with this disease and what matters to them when it comes to research. Our goal is to make PSC research as #patientcentered as possible. The weekend also gave me newfound appreciation for the work Arbor Research Collaborative for Health is doing as the data coordinating center for the WIND-PSC study. This innovative initiative is creating a FDA-quality real-world cohort to support the design of PSC clinical trials and serve as an external control arm. I’m proud to work on this study, and grateful to all the patients who lent their perspective on how to make it better.

We're #hiring a new Senior Editor II / Editor II in United States. Apply today or share this post with your network.